Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.
Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.